Skip to content
Article Rich – Lifestyle
Author:
Bexorg, Inc.
Bexorg Appoints Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors
October 27, 2026
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development
October 7, 2026
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
July 13, 2026